John Mendelsohn
About
In The Last Decade
John Mendelsohn
268 papers receiving 23.7k citations
Hit Papers
Peers
Comparison fields: 5 of 197
- Oncology 14.3k
- Molecular Biology 10.5k
- Pulmonary and Respiratory Medicine 6.3k
- Radiology, Nuclear Medicine and Imaging 5.8k
- Cancer Research 3.4k
Countries citing papers authored by John Mendelsohn
This map shows the geographic impact of John Mendelsohn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John Mendelsohn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John Mendelsohn more than expected).
Fields of papers citing papers by John Mendelsohn
This network shows the impact of papers produced by John Mendelsohn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John Mendelsohn. The network helps show where John Mendelsohn may publish in the future.
Co-authorship network of co-authors of John Mendelsohn
This figure shows the co-authorship network connecting the top 25 collaborators of John Mendelsohn. A scholar is included among the top collaborators of John Mendelsohn based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John Mendelsohn. John Mendelsohn is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 6 | |
| 2 | 10 | |
| 3 | 41 | |
| 4 | 29 | |
| 5 | 45 | |
| 6 | Epidermal growth factor receptor (EGFR) ubiquitination as a mechanism of acquired resistance to the anti-EGFR monoclonal antibody cetuximab | 3 |
| 7 | In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody. | 408 |
| 8 | 32 | |
| 9 | Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy. | 264 |
| 10 | Involvement of p27KIP1 in G1 arrest mediated by an anti-epidermal growth factor receptor monoclonal antibody. | 186 |
| 11 | 18 | |
| 12 | Expression of epidermal growth factor receptor and transforming growth factor alpha in human myogenic sarcomas | 1 |
| 13 | 21 | |
| 14 | Punishing the perpetrators of the Holocaust : the Ohlendorf and von Weizsaecker cases | 1 |
| 15 | Jewish emigration : the S.S. St. Louis affair and other cases | 0 |
| 16 | Jewish emigration from 1933 to the Evian conference of 1938 | 2 |
| 17 | Phase I trials of thymosin fraction 5 and thymosin α1 | 6 |
| 18 | Active tumor cell resistance to human natural killer lymphocyte attack. | 22 |
| 19 | Transfer of specific immunity with RNA. | 4 |
| 20 | Spontaneous lymphocyte proliferation and depressed cellular immunity in Hodgkin's disease. | 13 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.